Author:
LeCaer H, ,Barlesi F,Corre R,Jullian H,Bota S,Falchero L,Vergnenegre A,Dujon C,Delhoume J Y,Chouaid C
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Blakely LJ, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A, Walker MS (2009) A phase II trial of pemetrexed and gemcitabine as first-line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 66: 97–102
2. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies development and validation. J Chron Dis 40: 373–383
3. Corre R (2010) ESOGIA Trial.
http://clinicaltrials.gov/ct2/show/NCT01257139?term=corre&rank=1
(viewed on 30 December 2010)
4. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26: 4253–4259
5. Des Guetz G, Uzzan B, Morere JF, Perret G, Nicolas P (2010) Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Proc ASCO 2010 J Clin Oncol 28: 569S
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献